Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-01
2011-03-01
Sajjadi, Fereydoun G (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S913000
Reexamination Certificate
active
07897594
ABSTRACT:
An alkyl ether derivative represented by the following general formula [1]or its salt: wherein R1and R2represent each a substituent such as hydrogen, halogeno or alkyl; R3represents alkylamino, amino or hydroxyl; the ring A represents a 5- or 6-membered aromatic heterocycle or a benzene ring; m and n are each an integer of from 1 to 6; and p is an integer of from 1 to 3; shows an effect of protecting retinal nerve cells and, therefore, is useful as a preventive and/or a remedy for retinal nerve diseases such as glaucoma, diabetic retinopathy, retinal artery obstruction, retinal venous obstruction, macular degeneration and retinopathy of prematurity.
REFERENCES:
patent: 7087594 (2006-08-01), Saitoh et al.
patent: 7342043 (2008-03-01), Nakada et al.
patent: 2141729 (1995-08-01), None
patent: 0 873 990 (1998-10-01), None
patent: 1 325 744 (2003-07-01), None
patent: 2 521 136 (1983-08-01), None
patent: 7-304717 (1995-11-01), None
patent: 8-506807 (1996-07-01), None
patent: 8-511783 (1996-12-01), None
patent: 11-263773 (1999-09-01), None
patent: 4398247 (2009-10-01), None
patent: 95/00486 (1995-01-01), None
patent: 97/11054 (1997-03-01), None
patent: 02/30420 (2002-04-01), None
patent: 02/100833 (2002-12-01), None
patent: 03/035647 (2003-05-01), None
MedlinePlus, Retinal artery occlusion, Apr. 22, 2008, U.S. National Library of Medicine and National Institutes of Health, printed from http://www.nlm.nih.gov/medlineplus/ency/article/001028.htm on Apr. 7, 2010, 3 pages.
MayoClinic.com, Dry macular degeneration, Aug. 26, 2008, MayoClinic.com, printed from http://www.mayoclinic.com/health/macular-degeneration/DS00284/METHOD=print&DSECTION=all on Apr. 7, 2010, 13 pages.
Merck Manuals, Hereditary Optic Neuropathies, 2005, http://www.merck.com/mmpe/print/sec09/ch107/ch107b.html, printed May 27, 2008, 2 pages.
Masuzawa et al., A Model of Retinal Ischemia-Reperfusion Injury in Rats by Subconjunctival Injection of Endothelin-1, 2006,Experimental Biology and Medicine , 231:1085-1089.
Rosenbaum et al., Functional and Morphologic Comparison of Two Methods to Produce Transient Retinal Ischemia in the Rat, Mar. 2001, Journal of Neuro-Ophthalmology, 21(1):62-68.
Pang et al., Acute effects of glaucoma medications on rat intraocular pressure, Feb. 2005, Experimental Eye Research, vol. 80, Issue 2,207-214.
Newman, Hereditary Optic Neuropathies: From the Mitochondria to the Optic Nerve, Sep. 2005, American Journal of Ophthalmology, 140, 517-523.
Merck Manuals, Retinitis Pigmentosa, 2005, http://www.merck.com/mmpe/print/sec09/ch106/ch106h.html, printed May 27, 2008, 2 pages.
Youn et al., Effects of 400 nm, 420 nm, and 435.8 nm radiations on cultured human retinal pigment epithelial cells , 2009, Journal of Photochemistry and Photobiology B: Biology, vol. 95, Issue 1, pp. 64-70.
Rosenbaum, et al., Functional and Morphologic Comparison of Two Methods to Produce Transient Retinal Ischemia in the Rat, Journal of Neuro-Opthalmology, vol. 21, No. 1, pp. 62-68 (Mar. 2001).
Masuzawa, et al., A Model of Retinal Ischemia-Reperfusion Injury in Rats by Subconjunctival Injection of Endothelin-1, Experimental Biology and Medicine, vol. 231, pp. 1085-1089 (2006).
http//www.wrongdiagnosis.com, Prognosis of Age-related macular degeneration, http://www.wrongdiagnosis.com/a/age—related—macular—degeneration/prognosis.htm, 3 pages (printed May 7, 2009).
Pang, et al., Acute effects of glaucoma medications on rat intraocular pressure, Experimental Eye Research, vol. 80, No. 2, pp. 207-214 (Feb. 2005).
Mayo Clinic staff, Diabetic retinopathy-Treatments and drugs, www.mayoclinic.com, printed from http://www.mayoclinic.com/health/diabetic-retinopathy/DS00447/DSECTION=treatments%2Dand%2Ddrugs, 4 pages (2008) (printed on May 7, 2009).
The Foundation Fighting Blindness, Animal Models for Studying, Inherited Degenerative Retinal Disease, The Foundation Fighting Blindness, printed from www.retina-international.org/sci-news/animmod.doc , 23 pages (2000) (printed on Jan. 11, 2009).
Mayo Clinic Stargardt's disease: Can it be treated?, http://www.mayoclinic.com/print/stargardts-desease/AN00846/METHOD=print, 2 pages (2006).
National Eye Institute, Retinopathy of Prematurity (ROP), http://www.nei.nih.gov/helath/rop/, 6 pages (2008)(printed on May 7, 2009).
Zhang, et al., Activation of the Mitochondrial Apoptotic Pathyway in a Rat Model of Central Retinal Artery Occlusion, Investigative Opthalmology and Visual Science, vol. 46, pp. 2133-2139 (2005).
Newman, Hereditary Optic Neuropathies: From the Mitochondria to the Optic Nerve, American Journal of Opthalmology, vol. 140, pp. 517-523 (Sep. 2005).
Schmidt-Erfurth, et al., Management of neovascular age-related macular degeneration, Progress in Retinal and Eye Research, vol. 26, pp. 437-451 (2007).
Merck Manual Online Medical Library, Age-Related Macular Degeneration, Merck Manual-printed from http://www.merck.com/mmpe/print/sec09/ch106/ch106b.html, 2 pages (2005) (printed on Oct. 20, 2008).
Moalem, et al., Differential T cell response in central and peripheral nerve injury: connection with immune privilege, The FASEB Journal, vol. 13, pp. 1207-1217 (1999).
Stedman's Medical Dictionary 27thEdition, remedy, printed from http://www.thomsonhc.com/pdrel/librarian/PFDefaultActionld/pdrcommon.Stedmans 1 page (2000) (printed on Oct. 20, 2008).
Merck Manual Online Medical Library, Diabetic Retinopathy, Merck Manual-printed from http://www.merck.com/mmpe/print/sec09/ch106/ch106e.html, 2 pages (2005) (printed on Oct. 20, 2008).
Hyojun Ganka Gaku, 7thEdition, pp. 103-107, Igaku-Shoin Ltd. (1998).
Haruki, Abe: Atarashii Ganka, vol. 19, No. 7, pp. 903-912 (2002) (with English abstract).
“Agouron buys drug discovery company” “Chiroscience slaps up licensing talks”, SCRIP, No. 2229, p. 13 (May 6/9, 1997).
“Allergan's1997 sales fall”, SCRIP, No. 2307, p. 10 (Feb. 8, 1998).
U.S. Appl. No. 12/683,813, filed Jan. 7, 2010, Nakada, et al.
Iwakami Noboru
Kimura Tatsuo
Saitoh Akihito
Huang Gigi
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Sajjadi Fereydoun G
Toyama Chemical Co., Ltd.
LandOfFree
Preventive/remedy for retinal nerve diseases containing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventive/remedy for retinal nerve diseases containing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventive/remedy for retinal nerve diseases containing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731798